嵌合抗原受体-T细胞免疫疗法在多发性骨髓瘤中的研究进展

Advance in chimeric antigen receptor-T cell immunotherapy for multiple myeloma

近年来,多发性骨髓瘤(multiple myeloma,MM)的治疗取得了较大进展。尽管这种恶性肿瘤的预后有所改善,但经常以复发告终,因此亟需开发新的治疗方法。目前已经评估了针对B细胞成熟抗原(B cell maturation antigen,BCMA)、白细胞分化抗原19(cluster of differentiation 19,CD19)、白细胞分化抗原38(cluster of differentiation 38,CD38)和kappa轻链等多个靶点的嵌合抗原受体(chimeric antigen receptor,CAR)-T细胞,并在临床试验中取得了显著成果。但即使采用CAR-T细胞免疫疗法进行MM治疗,大多数患者仍会复发,这是该疗法的局限性。本文对CAR-T细胞免疫疗法在MM中的研究进展、治疗MM的局限性及其优化作一综述。

In recent years,considerable progress has been made in the treatment of multiple myeloma(MM).However,despite the current improved prognosis of this malignancy,it always ends in relapse and therefore new therapeutic approaches are urgently needed to overcome it.The chimeric antigen receptor(CAR)-T cells targeting B cell maturation antigen(BCMA),cluster of differentiation 19(CD19),cluster of differentiation 38(CD38) and kappa light chains have been evaluated,and have achieved remarkable results in clinical trials.However,even when MM is treated with CAR-T cell therapy,most patients eventually relapse,which is the greatest limitation of this therapy.This paperreviewedthe research progress,limitations and optimization of CAR-T cell immunotherapy in the treatment of MM.